The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
Matthew R. Zibelman
No relevant relationships to disclose
Yu-Ning Wong
No relevant relationships to disclose
Lois Malizzia
No relevant relationships to disclose
Alycia Corrigan
No relevant relationships to disclose
Anthony J. Olszanski
No relevant relationships to disclose
Crystal Shereen Denlinger
No relevant relationships to disclose
Susan K. Roethke
No relevant relationships to disclose
Colleen H. Tetzlaff
No relevant relationships to disclose
Gary R. Hudes
No relevant relationships to disclose
Elizabeth R. Plimack
Research Funding - Merck